High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression
Lung Cancer（2016）
摘要
•MET amplification as resistance to osimertinib.•Crizotinib provided temporary symptom relief.•Combination of Osiemrtinib+MET inhibitor should be investigated.
更多查看译文
关键词
Osimertinib,METamplification,Third-generation EGFR TKI,Acquired resistance,Non-small-cell lung cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要